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Prognostic Significance of B-cell Differentiation Genes Encoding Proteins 
in Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3
Aim To define prognostic significance of B-cell differentiation genes encoding 
proteins and BCL2 and BCL6 gene abnormalities in diffuse large B-cell lym-
phoma and follicular lymphoma grade 3 with >75% follicular growth pattern.
Methods In 53 patients with diffuse large B-cell lymphoma and 20 patients 
with follicular lymphoma grade 3 with >75% follicular growth pattern the 
following was performed: 1) determination of protein expression of BCL6, 
CD10, MUM1/IRF4, CD138, and BCL2 by immunohistochemistry; 2) sub-
classification into germinal center B-cell-like (GCB) and activated B-cell-like 
(ABC) groups according to the results of protein expression; 3) detection of 
t(14;18)(q32;q21)/IgH-BCL2 and BCL6 abnormalities by fluorescent in situ 
hybridization in diffuse large B-cell lymphoma and follicular lymphoma grade 
3 with >75% follicular growth pattern as well as in GCB and ABC groups; and 
4) assessment of the influence of the analyzed characteristics and clinical prog-
nostic factors on overall survival.
Results Isolated BCL6 expression was more frequently found in follicular lym-
phoma grade 3 with >75% follicular growth pattern than in diffuse large B-
cell lymphoma (P = 0.030). There were no differences in BCL2 and BCL6 gene 
abnormalities between diffuse large B-cell lymphoma and follicular lymphoma 
grade 3 with >75% follicular growth pattern. Diffuse large B-cell lymphoma and 
follicular lymphoma grade 3 with >75% follicular growth pattern patients were 
equally distributed in GCB and ABC groups. t(14;18)(q32;q21) was more fre-
quently recorded in GCB group, and t(14;18)(q32;q21) with BCL2 additional 
signals or only BCL2 and IgH additional signals in ABC group (P = 0.004). 
The GCB and ABC groups showed no difference in BCL6 gene abnormalities. 
There was no overall survival difference between the patients with diffuse large 
B-cell lymphoma or follicular lymphoma grade 3 with >75% follicular growth 
pattern; however, GCB group had longer overall survival than ABC group 
(P = 0.047). Multivariate analysis showed that BCL6, CD10, and BCL2 expres-
sion, BCL2 and BCL6 abnormalities, and International Prognostic Index were 
not significantly related to overall survival.
Conclusion Diffuse large B-cell lymphoma and follicular lymphoma grade 3 
with >75% follicular growth pattern patients have very similar characteristics 
and their prognosis is more influenced by protein expression of B-cell differen-
tiation stage genes than by tumor cells growth pattern, BCL2 and BCL6 abnor-
malities, and International Prognostic Index.
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The World Health Organization (WHO) 
classification defines diffuse large B-cell lym-
phoma as a specific type of mature B-cell neo-
plasm (1). However, diffuse large B-cell lym-
phoma types show clinical, morphological, 
immunophenotypic, and cytogenetic hetero-
geneity (2-7). Clinical heterogeneity of diffuse 
large B-cell lymphoma is a consequence of 
the expression of B-cell differentiation stage 
genes. The gene expression analysis has iden-
tified three prognostically significant molecu-
lar subtypes of diffuse large B-cell lymphoma 
as follows: germinal center B-cell-like (GCB), 
activated B-cell-like (ABC), and type 3 diffuse 
large B-cell lymphoma, which express neither 
genes of normal GCB-cells nor genes that are 
normally induced during in vitro activation of 
peripheral blood B-cells (8-10).
Immunohistochemical subclassification 
of diffuse large B-cell lymphoma showed that 
GCB and ABC groups greatly differ (11-19). 
Immunohistochemical GCB and ABC groups 
are not always considered to be prognostically 
significant predictors (16-19).
Cytogenetic analysis shows t(14;18) 
(q32;q21)/IgH-BCL2 to be more common in 
GCB than in ABC (20-24).
Follicular lymphoma is the second most 
common non-Hodgkin B-cell lymphoma (B 
NHL) (1,25). Follicular lymphoma grade 3, in 
contrast to indolent follicular lymphoma grade 
1 and follicular lymphoma grade 2, is clinically 
aggressive and has more in common with dif-
fuse large B-cell lymphoma (5).
The morphological subtypes of follicular 
lymphoma grade 3, follicular lymphoma grade 
3A, and follicular lymphoma grade 3B show 
morphological, immunohistochemical, and 
cytogenetic characteristics of variable clinical 
importance (1). Clinicopathologic evaluation 
revealed no differences in survival between 
follicular lymphoma grade 3A and follicular 
lymphoma grade 3B patients, yet follicular 
lymphoma grade 3 cases with a predominant 
diffuse component (>50%) had a significantly 
worse survival (25-27).
Follicular lymphoma grade 3 is char-
acterized by variable CD10 and BCL2 
protein expression and cytogenetic ab-
normalities, ie, rearrangements of BCL6 
gene, BCL2 gene amplification, and less 
common t(14;18)(q32;q21) (28). Both 
t(14;18)(q32;q21) and BCL2 protein ex-
pression are more common in follicular lym-
phoma grade 3A, while BCL6 gene rear-
rangements are more common in follicular 
lymphoma grade 3B (29-32).
Therapy and prognosis of patients with 
diffuse large B-cell lymphoma and follicu-
lar lymphoma are defined according to their 
morphological characteristics, clinical stage, 
and clinical prognostic factors included in the 
International Prognostic Index (IPI) (33,34).
The aim of this study was to determine 
whether follicular lymphoma grade 3 with 
>75% follicular growth pattern is part of the 
morphological, immunophenotypic, and cy-
togenetic spectrum of diffuse large B-cell lym-
phoma. For that purpose, we determined the 
following parameters: 1) protein expression 
of B-cell differentiation stage genes BCL6, 
CD10, MUM1/IRF4, CD138, and BCL2 
expression in patients with diffuse large B-
cell lymphoma and lymphoma grade 3; 2) 
subclassification into GCB and ABC groups 
according to the results of protein expression 
profile; 3) t(14;18)(q32;q21)/IgH-BCL2 
and abnormalities of BCL6 gene in diffuse 
large B-cell lymphoma and follicular lym-
phoma grade 3 with >75% follicular growth 
pattern, as well as in GCB and ABC groups; 
and 4) the influence of protein expression, 
cytogenetic abnormalities, and clinical prog-
nostic factors of age, sex, Ann Arbor clinical 
stage, and IPI risk group on overall survival 
(35,36).
Borovečki et al: Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3
627
Patients and methods
The study included 73 patients with lymph 
node enlargement who were diagnosed with 
primary diffuse large B-cell lymphoma (n = 53) 
or follicular lymphoma grade 3 with >75% fol-
licular growth pattern (n = 20) according to 
the WHO classification during the 2000-2004 
period. Patients’ data were obtained from pa-
thology files of the Merkur University Hos-
pital and Zagreb University Hospital Center, 
Zagreb. The morphological features of all cas-
es were examined on paraffin-embedded lymph 
node sections (by MD and A.B.). The patients 
were selected on the basis of adequate lymph 
node morphology and availability of histolog-
ic material for immunohistochemical and fluo-
rescent in situ hybridization (FISH) analysis at 
diagnosis. The lymph node morphology crite-
ria were based on the WHO classification diag-
nostic criteria for diffuse large B-cell lymphoma 
as follows: diffuse growth pattern of large trans-
formed lymphoid cells, predominantly cento-
blastic and immunoblastic morphology, im-
munohistochemicaly phenotype CD20+CD3–, 
and follicular lymphoma grade 3 with >75% 
follicular growth pattern with >15 centroblast 
per high-power field and present centrocytes, 
immunohistochemically CD20+CD3–.
Patients were followed-up at three insti-
tutions (Merkur University Hospital, Dubra-
va University Hospital, and Zagreb Univer-
sity Hospital Center). The clinical data were 
available for 64 of 73 patients. The median fol-
low-up was 19 months (1-1843 days). Data 
on therapy were not available for one patient. 
Of the remaining 63 patients, 39 received che-
motherapy as first-line therapy according to 
the CHOP (cyclophosphamide, doxorubi-
cin, vincristine, prednisone) regimen and 3 of 
these patients received additional radiothera-
py (37). Three of 63 patients received CHOP 
plus rituximab regimen and 4 of 63 patients 
received COP (cyclophosphamide, vincristine, 
prednisone) regimen (37). Nine of 63 patients 
were initially treated with ProMACE, M-BA-
COD, BACOP, or EPOCH regimens, and six 
of 63 patients underwent additional periph-
eral blood stem cell transplantation (37). One 
patient died before treatment was started and 
one patient refused any therapy.
The study was approved by ethics commit-
tees of the Merkur University Hospital and 
Zagreb University School of Medicine.
Paraffin-embedded lymph node sections 
were analyzed with immunohistochemistry 
and FISH method; in cases where adequate 
material was available, tissue microarray was 
used. For tissue microarray, two representa-
tive 3-mm cores were obtained by use of biop-
sy needle (11G, Somatex, Teltow, Germany) 
and manually inserted into a paraffin block in 
a gird pattern.
Immunohistochemistry
Formalin-fixed, 4-µm thick paraffin sections 
were deparaffinized, rehydrated, and stained 
with antibodies to CD20 (clone L26, DAKO, 
Glostrup, Denmark; dilution 1:200), CD3 
(polyclonal, DAKO; dilution 1:50), BCL6 
(clone P1F6, Novocastra, Newcastle, UK; di-
lution 1:20), CD10 (clone 56C6, Novocas-
tra; dilution 1:20), MUM1/IRF4 (polyclonal, 
Santa Cruz Biotechnology, Santa Cruz, CA, 
USA; dilution 1:100), CD138 (clone 5F7, 
Novocastra; dilution 1:50), and BCL2 (clone 
124, DAKO; dilution 1:10). Heat-induced 
antigen retrieval by pressure cooking treat-
ment PASCAL (DAKO) was performed for 
CD10, BCL6, MUM1/IRF4, and CD138 in 
1 mmol EDTA solution, pH 8.0, at 125˚C for 
30 seconds, and for BCL2 in microwave oven 
in Target Retrieval solution, pH 6.0, (DAKO) 
at 95˚C for 15 minutes. The EnVision meth-
od (DAKO) was used for immunostain-
ing according to the manufacturer’s instruc-
tions. Sections were stained in an autostainer 
(DAKO) and counterstained with hematoxy-
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lin. Cases were considered positive if 30% of 
tumor cells were stained with an antibody.
Patients were clustered into GCB and 
ABC groups according to the immunophe-
notypic profile criteria described by Hans et 
al (11). Cases were assigned to GCB group if 
CD10 or both CD10 and BCL6 were positive. 
If CD10 and BCL6 were negative, the cases 
were assigned to ABC group. The cases with 
negative CD10 and positive BCL6 expression 
were classified according to MUM1/IRF4 ex-
pression: the GCB group was MUM1/IRF4 
negative and the ABC group was MUM1/
IRF4 positive.
Fluorescent in situ hybridization
Tissue sections were analyzed with dual 
color, dual fusion translocation probe 
t(14;18)(q32;q21)/IgH-BCL2 (Vysis Inc., 
Downers Grove, IL, USA), and dual color 
break-apart rearrangement probe BCL6 (Vy-
sis Inc.) (38).
To analyze hybridization, a total of 200 
nuclei per case were scored for the presence of 
gene signals. A cut-off of 7% was used to de-
fine a positive case.
Statistical analysis
The χ2 test was used to compare the differenc-
es in proportions. The t test was used to eval-
uate the difference in age between the patient 
groups. Kaplan-Meier survival analysis was per-
formed and the curves were compared by Cox-
Mantel U-test. Overall survival time was calcu-
lated from the date of diagnosis until the last 
follow-up visit or death. Alive patients were 
censored in the analysis. Multivariate analy-
sis was performed with the Cox stepwise pro-
portional hazards model. Variables considered 
in the analysis were BCL6, CD10, and BCL2 
protein expression, IPI risk group (group 1 
– IPI score 0, 1, and 2; group 2 – IPI score 3, 
4, and 5), BCL2 gene abnormality groups (1 
– no abnormalities; 2 – (14,18)(q32;q21)/
IgH-BCL2; 3 – BCL2 additional signals; 4 – 
t(14;18)(q32;q21)/IgH-BCL2 and BCL2 ad-
ditional signals; 5 – IgH additional signals), 
and BCL6 gene abnormality groups (1 – no 
abnormalities; 2 – BCL6 translocation; 3 – 
BCL6 additional signals; 4 - BCL6 transloca-
tion and BCL6 additional signals). Statistical 
analysis was performed with the STATISTI-
CA software, version 7.0 (StatSoft Inc. Tulsa, 
OK, USA). The level of significance was set at 
P < 0.05.
Results
Patients with diffuse large B-cell lymphoma 
were significantly older and had higher IPI 
Table 1. Clinical characteristics of patients with diffuse large B-
cell lymphoma (DLBCL) and follicular lymphoma grade 3 (FL-3) 
with >75% follicular growth pattern (FGP) and immunohisto-
chemical stain results at diagnosis*
No. of patients
Characteristics
diffuse large
B-cell
lymphoma
(n = 53)
follicular lymphoma
grade 3 with >75%
follicular growth
pattern (n = 20) P
Age (years, median [range]) 66 (23-91) 58 (25-79) 0.027†
Sex: 0.551‡
 male 28  9
 female 25 11
Ann Arbor stage (n = 64):§ 0.099‡
 I 10  5
 II 13  2
 III 10  8
 IV 14  2
IPI risk group (n = 64):║ 0.048‡
 1 26 14
 2 21  3
CD10: 0.146‡
  - 43 13
 + 10  7
BCL6: 0.030‡
  - 36  8
 + 17 12
MUM1/IRF4: 0.513‡
  -  3  2
 + 50 18
CD138: 0.536‡
  - 52 20
 +  1  0
BCL2: 0.717‡
  - 21  7
 + 32 13
GCB 10  7 0.146‡
ABC 43 13
*Abbreviations: GCB – germinal center B-cell-like; ABC – activated B-cell-like;+ – posi-
tive expression; - – negative expression; IPI – International Prognostic Index.
†t test = 2.26, df = 71.
‡χ2 test.
§Ann Arbor stage (35).
IIInternational Prognostic Index (36) score group 1 – low risk and low intermediate risk; 
score group 2 – high intermediate risk and high risk.
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score than did patients with follicular lympho-
ma grade 3 with >75% follicular growth pat-
tern (Table 1). However, there were no dif-
ferences in sex distribution and Ann Arbor 
clinical stage between the two patient groups. 
The BCL6 protein expression was more fre-
quently found in patients with follicular lym-
phoma grade 3 with >75% follicular growth 
pattern, whereas no differences between the 
two patient groups were recorded in CD10, 
MUM1/IRF4, CD138, and BCL2 expression.
The protein expression profiles of BCL6, 
CD10, and MUM1/IRF4 were analyzed ac-
cording to the criteria described by Hans et al 
(11). In 73 patients, the following 5 patterns 
of protein expression were found. The CD10+ 
BCL6+MUM1/IRF4– pattern was found in 3 
cases; the CD10+BCL6–MUM1/IRF4+ in 6 
cases; the CD10+BCL6+MUM1/IRF4+ in 8 
cases; the CD10–BCL6+MUM1/IRF4+ in 18 
cases; and the CD10–BCL6–MUM1/IRF4+ 
in 38 cases. The first three patterns were classi-
fied as GCB profile and the latter two patterns 
were present as ABC profile. The distribution 
of cases according to the immunophenotypic 
profile criteria is shown in Table 1. The GCB 
profile (Figure 1) was found in 10 of 53 cases 
and ABC profile in 43 of 53 cases of diffuse 
large B-cell lymphoma. The GCB profile was 
present in 7 of 20 cases and ABC profile (Fig-
ure 2) in 13 of 20 cases of follicular lymphoma 
grade 3 with >75% follicular growth pattern 
(χ2 test, P = 0.146).
There was no difference in BCL2 pro-
tein expression between the GCB and ABC 
groups. BCL2 protein expression was found in 
10 of 17 GCB and 35 of 56 ABC cases.
Cytogenetic abnormalities of diffuse large B-
cell lymphoma and follicular lymphoma grade 3 
with >75% follicular growth pattern cases, and 
GCB and ABC groups are shown in Table 2. 
FISH analysis of t(14;18)(q32;q21)/IgH-BCL2 
detected BCL2 gene translocation and BCL2 or 
IgH gene additional signals. t(14;18)(q32;q21)/
IgH-BCL2 was detected in 5 of 50 cases of dif-
fuse large B-cell lymphoma and 7 of 20 cases of 
follicular lymphoma grade 3 with >75% follic-
ular growth pattern. BCL2 gene additional sig-
nals (Figure 3) were detected in 8 of 50 cases of 
diffuse large B-cell lymphoma and 2 of 20 fol-
licular lymphoma grade 3 with >75% follicular 
Figure 1. Diffuse large B-cell lymphoma, immunohistochemical ger-
minal center B-cell-like patient group; (A) hematoxylin-eosin staining; 
(B) positive immunohistochemical staining for CD10; (C) negative im-
munohistochemical staining for BCL6; (D) positive immunohistochem-
ical staining for MUM1/IRF4 ( × 400 magnification).
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growth pattern cases. Translocation and BCL2 
gene additional signals (Figure 4) were present 
in 2 of 50 cases of diffuse large B-cell lympho-
ma and 2 of 20 cases of follicular lymphoma 
grade 3 with >75% follicular growth pattern. 
t(14;18)(q32;q21)/IgH-BCL2 was found in 8 
of 17 GCB patients and 4 of 53 ABC patients. 
Also, BCL2 gene additional signals were signifi-
cantly more common in ABC group, as well as 
translocation and BCL2 gene additional signals 
(χ2 test, P = 0.004).
BCL6 gene translocation was present in 7 
of 51 cases of diffuse large B-cell lymphoma 
and 4 of 20 cases of follicular lymphoma grade 
3 with >75% follicular growth pattern. BCL6 
gene additional signals were found in 14 of 51 
cases of diffuse large B-cell lymphoma and 4 of 
20 cases of follicular lymphoma grade 3 with 
>75% follicular growth pattern. Also, BCL6 
gene translocation and BCL6 gene addition-
al signals were found in 5 of 51 cases of dif-
fuse large B-cell lymphomas and 1 of 20 cas-
es of follicular lymphoma grade 3 with >75% 
follicular growth pattern. There were no sig-
nificant differences between GCB and ABC 
groups in the four patterns of BCL6 gene ab-
normalities.
Figure 2. Follicular lymphoma grade 3, immunohistochemical acti-
vated B-cell-like patient group; (A) hematoxylin-eosin staining; (B) 
negative immunohistochemical staining for CD10; (C) negative immu-
nohistochemical staining for BCL6; (D) positive immunohistochemical 
staining for MUM1/IRF4 ( × 400 magnification).
Figure 3. BCL2 and IgH genes additional signals (fluorescent in situ 
hybridization, ×1000 magnification).
Figure 4. t(14;18)(q32;q21)/IgH-BCL2 and additional BCL2 and IgH 
signals (fluorescent in situ hybridization, ×1000 magnification).
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There was no difference in the overall sur-
vival between the patients with diffuse large 
B-cell lymphoma and patients with follicu-
lar lymphoma grade 3 with >75% follicular 
growth pattern (Figure 5). Multivariate analy-
sis included data on 59 patients with complete 
information for all variables. None of the vari-
ables was a significant predictor of overall sur-
vival (Wald χ25 test = 8.260, P = 0.143).
However, overall survival was significant-
ly better in GCB group (Figure 6). Clinical 
characteristics analysis of the GCB and ABC 
patient groups yielded a significant difference 
only according to the Ann Arbor clinical stage 
at diagnosis (Table 3). ABC patients were 
more often in an advanced clinical stage at di-
agnosis than GCB patients, without any dif-
ference according to age, sex, and IPI risk.
Discussion
Our study showed that there were no differ-
ences in protein expression between patients 
with diffuse large B-cell lymphoma and those 
Figure 5. Overall survival distribution (Kaplan-Meier) of patients with diffuse large B-cell 
lymphoma (DLBCL) or follicular lymphoma grade 3 (FL-3) with >75% follicular growth 
pattern (FGP). Circle represents complete follow-up; plus represents censored follow-up 
(Cox-Mantel U-test = 2.463; P = 0.341); full line represents DLBCL; broken line repre-
sents FL-3 > 75% FGP.
Table 2. Cytogenetic abnormalities of diffuse large B-cell lymphoma and follicular lymphoma grade 3 with >75% follicular growth pattern 
and germinal center B-cell-like (GCB) and activated B-cell-like (ABC) patient groups
Patients group Cytogentic abnormalities Total P*
t(14;18)(q32;q21)/IgH-BCL2† 0.090
 1 2  3 4 5
Diffuse large B-cell lymphoma 29 5  8 2 6 50
Follicular lymphoma grade 3 with >75% follicular growth pattern  8 7  2 2 1 20
3q27‡ 0.759
 1 2  3 4
Diffuse large B-cell lymphoma 25 7 14 5 51
Follicular lymphoma grade 3 with >75% follicular growth pattern 11 4  4 1 20
t(14;18)(q32;q21)/IgH-BCL2 0.004
 1 2  3 4 5
GCB  7 8  1 1 0 17
ABC 30 4  9 3 7 53
3q27 0.517
 1 2  3 4
GCB 10 3  4 0 17
ABC 26 8 14 6 54
*χ2 test.
†1 – no abnormalities; 2 – t(14;18)(q32;q21)/IgH-BCL2; 3 – BCL2 additional signals; 4 – t(14;18)(q32;q21)/IgH-BCL2 and BCL2 additional signals; 5 – IgH additional signals.
‡1 – no abnormalities; 2 – BCL6 translocation; 3 – BCL6 additional signals; 4 – BCL6 translocation and BCL6 additional signals.
Table 3. Clinical characteristics of immunohistochemical ger-
minal center B-cell-like (GCB) and activated B-cell-like (ABC) 
patient groups
GCB* ABC P
n 17 56
Age (years, median [range]) 63 (25-85) 64 (23-91) 0.962*
Sex (men/women)  9/8 28/28 0.832†
Ann Arbor stage (total 64):‡ 0.025†
 I  2 13
 II  2 13
 III  8 10
 IV  1 15
IPI risk group (total 64):§ 0.470†
 1  7 33
 2  6 18
*t test = 0.048, df = 71.
†χ2 test risk.
‡Ann Arbor stage (35).
§International Prognostic Index (36) score group 1 – low risk and low intermediate 
risk; score group 2 – high intermediate and high.
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with follicular lymphoma grade 3 with >75% 
follicular growth pattern, but there were dif-
ferences in the presence of BCL6, BCL2, and 
BCL6 cytogenetic abnormalities. Although 
patients with diffuse large B-cell lymphoma 
and follicular lymphoma grade 3 with >75% 
follicular growth pattern had a significant-
ly different IPI risk at diagnosis, they showed 
similar overall survival. Also, diffuse large B-
cell lymphoma and follicular lymphoma grade 
3 with >75% follicular growth pattern were 
equally distributed between GCB and ABC 
groups. However, GCB had longer overall 
survival than ABC group. t(14;18)(q32;q21) 
was more frequently recorded in GCB group, 
whereas t(14;18)(q32;q21) with BCL2 addi-
tional signals or only BCL2 and IgH addition-
al signals were more frequent in ABC group; 
however, no differences in BCL6 gene ab-
normalities were observed. Also, multivariate 
analysis showed that BCL6, CD10, and BCL2 
expression, BCL2 and BCL6 abnormalities, 
and IPI were not significantly related to over-
all survival.
In the WHO classification, diffuse large B-
cell lymphoma and follicular lymphoma grade 
3 are two morphologically and clinically sepa-
rate types of B NHL (1). However, the clini-
cal course of these two types of B NHL has 
very similar clinical outcomes (39). Hans et al 
(11) showed, by correlating subclassification 
according to gene expression with subclassifi-
cation according to protein expression in dif-
fuse large B-cell lymphoma, that the protein 
expression profile of GCB and ABC groups 
was significantly predictive of overall survival. 
However, it was not uniformly confirmed as a 
significant predictor (11-19).
Different overall survival in GCB and ABC 
groups may depend on the therapy regimen. 
According to Nyman et al (40), in patients 
treated with immunochemotherapy GCB and 
ABC groups seem to lose their prognostic val-
ue. In the present study, only three of 63 pa-
tients received CHOP plus rituximab thera-
py regimen and the prognostic significance of 
GCB protein expression profile could not be 
abolished by rituximab treatment.
CD10 and BCL6 are considered germinal 
center differentiation stage-specific markers. 
However, CD10 is characterized by decreased 
expression in follicular lymphoma grade 3 
in contrast to indolent follicular lymphoma 
grade 1 and follicular lymphoma grade 2 (41). 
In the present study, CD10 expression was 
found in only 35% of cases of follicular lym-
phoma grade 3 with >75% follicular growth 
pattern and 19% of cases of diffuse large B-cell 
lymphoma. Also the more common BCL6 ex-
pression in follicular lymphoma grade 3 with 
>75% follicular growth pattern than in dif-
fuse large B-cell lymphoma indicates that the 
BCL6 protooncogene controls reactive germi-
nal centers formation as well as formation of 
neoplastic follicles in FL-3 (42).
MUM1/IRF4 expression is present in 
non-neoplastic lymph node in a small number 
of late centrocytes and mostly in postgermina-
tive B-cells, so it is considered as postgerminal 
differentiation stage-specific marker (43,44). 
Figure 6. Overall survival distribution (Kaplan-Meier) in immunohistochemical germinal center 
B-cell-like (GCB) and activated B-cell-like (ABC) patient group; circle represents complete 
follow-up; plus represents censored follow-up (Cox-Mantel U-test = 4.309; P = 0.047); full line 
represents GCB; broken line represents ABC.
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According to Shaffer et al (3), the high per-
centage of MUM1/IRF4 protein-positive dif-
fuse large B-cell lymphoma cases, which was 
found in the present study, relates neoplas-
tic B-cells in diffuse large B-cell lymphoma 
to postgerminal center differentiation block. 
Also, a large number of MUM1/IRF4 positive 
follicular lymphoma grade 3 cases indicate the 
probable late centrocyte origin of neoplastic 
B-cells or oncogenic translocation at an early 
stage of B-cell differentiation and consequent-
ly the transformed B-cell arrest at a later stage 
of differentiation (3). Zu et al (45) showed 
that interpretation of immunohistochemis-
try staining and scoring of MUM1/IRF4 var-
ied greatly, with an average of only 30-37% 
complete agreement among observers. Also, in 
the present study the number of diffuse large 
B-cell lymphoma cases with ABC protein ex-
pression profile was higher than the number of 
cases recorded in literature (3,9,10,12). There-
fore, we agree with de Jong et al (46) that stan-
dardization of immunohistochemistry tech-
niques and centralized consensus review when 
using immunohistochemical markers are man-
datory.
Negative expression of CD138 in our fol-
licular lymphoma grade 3 with >75% follicular 
growth pattern cases and very low expression 
in diffuse large B-cell lymphoma cases, mostly 
with centroblast and immunoblast morpholo-
gy, confirmed CD138 as a protein specific for 
terminal B-cell differentiation stage.
t(14;18)(q32;q21) represented an initial 
mechanism in the pathogenesis of GCB group, 
while BCL2 gene additional signals were more 
frequently present in ABC group. BCL2 and 
BCL6 gene additional signals observed in the 
present study could indicate either additional 
chromosomes 18 and 3 or gene amplification 
(20). t(14;18)(q32;q21) was more frequent-
ly found in GCB group and BCL2 additional 
signals in ABC group (19-24). Our study re-
vealed that t(14;18)(q32;q21) and BCL2 gene 
additional signals were not mutually exclusive-
ly present in the GCB and ABC groups.
In our study, there were no between-group 
differences in BCL6 gene abnormalities. Bar-
rans et al (47) found BCL6 gene rearrange-
ment and BCL2 expression in ABC group of 
patients with shorter overall survival. Bea et al 
(48) found additional BCL6 gene signals only 
in ABC group. In the present study, addition-
al BCL6 signals were also detected in the GCB 
group.
In conclusion, the similarity between dif-
fuse large B-cell lymphoma and follicular lym-
phoma grade 3 could be examined by tumor 
cells growth pattern, protein expression of B-
cell differentiation stage genes, common cy-
togenetic abnormalities, or clinical prognos-
tic factors. The present study analyzed, for 
the first time, only follicular lymphoma grade 
3 with >75% follicular growth pattern to ex-
clude the influence of diffuse growth pattern 
component for inferior survival in grade 3 fol-
licular lymphoma. Also, our results showed 
very similar characteristics of diffuse large B-
cell lymphoma and follicular lymphoma grade 
3 cases and implied that protein expression of 
the B-cell differentiation stage genes could be 
a superior prognostic factor than tumor cells 
growth pattern, cytogenetic abnormalities of 
BCL2 and BCL6 genes, and clinical prognos-
tic factors.
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